Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acceptability and satisfaction of dienogest in symptomatic endometriosis
ISRCTN68041248Phase 4Completed
- Sponsor
- Exeltis
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dienogest in endometriosis, sponsored by Exeltis. Primary endpoints: Endometriosis-associated pain symptoms at 3 months and Endometriosis-associated pain symptoms at 6 months. Started Mar 2024; status: completed.
02
Drugs
dienogest
03
Conditions
endometriosis
Beyond the preview
Go deeper on ISRCTN68041248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN68041248.